A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib

Trial Profile

A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Momelotinib (Primary)
  • Indications Anaemia; Myelofibrosis; Polycythaemia vera; Thrombocytopenia; Thrombocytosis
  • Focus Registrational; Therapeutic Use
  • Acronyms Simplify 2
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 25 Jun 2017 Results assessing superiority of momeloitinib versus best available therapy in patients with myelofibrosis, presented at the 22nd Congress of the European Haematology Association.
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 16 Nov 2016 Top-Line Results published in a Gilead Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top